Skip to main content
. 2022 Sep 20;119(39):e2117988119. doi: 10.1073/pnas.2117988119

Fig. 1.

Fig. 1.

Identification of lncRNA TGFB-AS1, which is associated with good prognosis in TNBC patients. (A) Heat-map representation of lncRNAs that are differentially expressed in MDA-231 cells and LM2 cells. The red arrow points to TGFB2-AS1. (B and C) TGFB2-AS1 expression of stage I/II compared with stage III/IV in basal (B) and all subtypes of breast cancers (C) analyzed using the TCGA database. (D and E) Kaplan–Meier analyses of the correlation between TGFB2-AS1 levels and the overall survival in patients with all subtypes (D) and basal-like (E) breast cancer using the TCGA database (log rank test). (F) Representative images of ISH staining of TGFB2-AS1 in stage I/II and stage III in TNBC tissues from cohort 1. (Scale bar, 200 μm.) (G and H) TGFB2-AS1 ISH score quantitative data of stage I/II compared with stage III/IV in TNBC tissues from cohort 1 (G) and cohort 2 (H). (I–L) Kaplan–Meier analyses of the correlation between TGFB2-AS1 levels and the DFS (I and J) and OS (K and L) in two TNBC cohorts (log rank test). Error bars represent mean ± SEM, *P < 0.05. Statistical significance was assessed using two-tailed Student’s t test. Determination of the optimal cutoff value for predicting survival was performed using X-tile bioinformatics software version 3.6.1.